Position in EXEL
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$19,424
-$2,321 QoQ
Shares Held
357
-29.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#646
of 751 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Byrne Asset Management LLC holds $220,999 across 8 Biotechnology names. EXEL ranks #2 (8.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRVO |
CervoMed Inc.
|
51,250 | $158,875 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
357 | $19,424 | |
| 3 | INCY |
Incyte Corp
|
165 | $18,704 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22 | $13,717 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
|
80 | $6,261 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
16 | $3,855 | |
| 7 | AUTL |
Autolus Therapeutics plc
|
100 | $160 | |
| 8 | ELDN |
Eledon Pharmaceuticals, Inc.
|
1 | $3 |
All Filings in EXEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,424 | 357 | Shares | Sole | 2026-07-07 | |
| 2026-03-31 | $21,745 | 507 | Shares | Sole | 2026-04-02 | |
| 2025-12-31 | $10,519 | 240 | Shares | Sole | 2026-01-12 | |
| 2025-09-30 | $15,694 | 380 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $31,296 | 710 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $11,445 | 310 | Shares | Sole | 2025-04-16 | |
| 2024-12-31 | $10,323 | 310 | Shares | Sole | 2025-01-28 | |
| No filing history on record for this holder in this stock. | ||||||